[HTML][HTML] Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF …
KB Kim, R Kefford, AC Pavlick, JR Infante… - Journal of Clinical …, 2013 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2013•ncbi.nlm.nih.gov
Purpose BRAF mutations promote melanoma cell proliferation and survival primarily through
activation of MEK. The purpose of this study was to determine the response rate (RR) for the
selective, allosteric MEK1/MEK2 inhibitor trametinib (GSK1120212), in patients with
metastatic BRAF-mutant melanoma.
activation of MEK. The purpose of this study was to determine the response rate (RR) for the
selective, allosteric MEK1/MEK2 inhibitor trametinib (GSK1120212), in patients with
metastatic BRAF-mutant melanoma.
Abstract
Purpose
BRAF mutations promote melanoma cell proliferation and survival primarily through activation of MEK. The purpose of this study was to determine the response rate (RR) for the selective, allosteric MEK1/MEK2 inhibitor trametinib (GSK1120212), in patients with metastatic BRAF-mutant melanoma.
ncbi.nlm.nih.gov